Oct 28, 6:34 AM ET
Boston Scientific Corporation announced its third quarter 2026 financial results, reporting net sales of $5.138 billion, a 1.5 percent increase compared to the prior year period. GAAP net income attributable to common stockholders was $582 million, or $0.40 per share, while adjusted EPS reached $0.73.
- Generated third quarter 2026 net sales of $5.138 billion, up 1.5 percent reported, operational, and organic year-over-year.
- Reported GAAP net income attributable to common stockholders of $582 million, or $0.40 per share, and adjusted EPS of $0.73.
- Estimated full-year 2026 organic net sales growth of approximately 3.75 percent and adjusted EPS of $3.16 to $3.18.
Read the filing on SEC.gov ↗
Oct 7, 6:11 AM ET
Boston Scientific said Joe Fitzgerald, currently executive vice president and group president of Cardiovascular, will become executive vice president and chief operating officer effective January 1, 2027. The company also plans three new reportable segments effective the same date, and it named Mark Bickel as chief accounting officer effective March 1, 2027, succeeding Emily Woodworth.
- Fitzgerald's offer letter sets an annual base salary of $1,050,000 and a bonus target of 110% of base salary.
- His 2027 annual equity award has a total grant date fair value of $7,000,000, expected in February 2027.
- Three reportable segments take effect January 1, 2027: Interventional Therapies, Rhythm Solutions and MedSurg.
- Mark Bickel, 49, will become Senior Vice President, Global Accounting Controller and Chief Accounting Officer on March 1, 2027.
Read the filing on SEC.gov ↗
Sep 23, 6:01 AM ET
Boston Scientific said Executive Vice President and Group President Arthur C. Butcher will retire from his role on January 1, 2027, and remain as a senior advisor through February 26, 2027. The filing says the company expects a retirement agreement with payments and benefits materially consistent with his existing plan terms.
- Butcher informed the company of his retirement decision on September 21, 2026.
- He leads MedSurg and Asia Pacific as Group President; retirement is effective January 1, 2027.
- As senior advisor, his current annual base salary is $780,000, prorated through the Retirement Date.
- The Retirement Date is February 26, 2027, or any earlier date.
Read the filing on SEC.gov ↗
Sep 8, 6:15 AM ET
Boston Scientific said a cybersecurity incident identified on August 25, 2026 caused a global disruption to its operations, including manufacturing, order processing and shipping. The company believes the incident is likely to materially affect its third quarter and full year 2026 results, and it is unlikely to meet the net sales growth and adjusted EPS guidance it gave on July 29, 2026. The filing does not quantify the financial impact, and the company says the full effects are not yet known.
- Incident identified August 25, 2026; the company activated incident response protocols with third-party cybersecurity experts.
- Company is unlikely to meet previously provided net sales growth and adjusted EPS guidance for Q3 and full year 2026 (guidance issued July 29, 2026).
- Major distribution centers are processing and shipping at or above normal levels, and manufacturing has resumed across most facilities; full recovery timing is uncertain.
- Updated outlook for the rest of 2026 is expected on the Q3 earnings call on Wednesday, October 28, 2026; the company does not expect a material long-term impact on its financial condition.
Read the filing on SEC.gov ↗
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.